Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Maintains $116 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Ascendis Pharma (ASND) and kept the price target at $116.

April 22, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on Ascendis Pharma with a $116 price target.
The maintenance of an Equal-Weight rating and a steady price target by a major analyst like Morgan Stanley suggests a neutral outlook on ASND's stock in the short term. This indicates that while there are no immediate negative signals, there also aren't strong positive catalysts expected to significantly move the stock price. Investors may view this as a signal to hold their positions while monitoring the company for any future developments that could impact its valuation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100